Generalized Anxiety Disorder
Conditions
Brief summary
This is an open-label flexible-dose pilot study evaluating the efficacy, safety, and tolerability of Pristiq (desvenlafaxine) in outpatient subjects diagnosed with Generalized Anxiety Disorder (GAD) with or without comorbidities that are secondary to the GAD. Primary trial objective is to evaluate the efficacy of Pristiq (desvenlafaxine) SNRI treatment 50 to 100 mg once daily in the treatment of GAD with or without comorbidities. Secondary trial objective is to determine whether or not treatment outcome in GAD is related to changes in cortical prefrontal activity of norepinephrine.
Interventions
DRUGDesvenlafaxine
Sponsors
START Clinic for Mood and Anxiety Disorders
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open Label.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* The patient has provided signed informed consent. * Outpatients aged 18-65 (extremes included). * Patients with a primary diagnosis of GAD according to DSM IV (300.23) criteria (diagnosis to be made using the Mini International Neuropsychiatric Interview; MINI Version 6.0.0). Patients with co-morbid anxiety disorders will be permitted, as long as GAD is judged to be the primary diagnosis. * Patients who score a HAM-A of ≥ 20 at both Screening and Baseline, and ≥ 10 on the psychic and somatic anxiety factors. * On the basis of physical examination, medical history, and basic laboratory screening, patient is, in the investigator's opinion, in a suitable condition. * Willing and able to attend study appointments in the correct time windows.
Exclusion criteria
* Any other axis I diagnosis that was a primary disorder in the previous six months. * Alcohol or drug abuse as defined in the DSM IV (300.23) within the last six months. * Mania, hypomania as defined in the DSM IV (300.23). * Any psychotic disorder. * Eating disorders as defined in the DSM IV (300.23). * Any cognitive disorder or dementia within 3 months before the baseline visit. * Clinical interpretation of apparent suicide risk. * Continuation or commencement of formal psychotherapy. * Current use of or commencement of antidepressant and anxiolytic medications. * Failure on no more than 2 antidepressants (either SSRIs or SNRIs to exclude any treatment resistance. * Patients, who have been on an antidepressant or other anxiolytic prior to the study, will have discontinued it more than two weeks prior to entry into the study. Those who have been on fluoxetine, will have been off of it for at least 5 weeks. * Patients who have been on a herbal or alternative treatment judged to be potentially anxiolytic or with psychobiological activity (e.g. St. John's Wort, S-adenosylmethionine), will have terminated usage of the agent more than two weeks prior to entering the study. * Scores on the Hamilton Depression Rating Scale (HAM-D) \> 15, at screening visit 1 * Laboratory values at screening or in medical history that may be considered through clinical interpretation to be significant. * Diseases that could through clinical interpretation interfere with the assessments of safety, tolerability and efficacy. * Serious illness: Liver or renal insufficiency, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic or metabolic disturbance. * If female, the subject is pregnant or lactating or intending to become pregnant before, during or within 30 days after participating in this study; or intending to donate ova during such time period. * The subject has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening. * The patient is, in the opinion of the investigator, unlikely to comply with the clinical trial protocol or is unsuitable for any reason. * Known allergy or intolerance to desvenlafaxine or its excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean changes in the Hamilton Anxiety Rating Scale from baseline visit to week 16. | 16 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Mean change from baseline to week 16 on the measures of prefrontality including: Frontal System Behavioural Scale and Behaviour Rating Inventory of Executive Function-Adult | 16 weeks |
Countries
Canada
Outcome results
None listed